Escin IA
[CAS# 123748-68-5]

Identification

• Classification: Biochemical >> Plant extracts
• Name: Escin IA
• Synonyms: Aescin IA; (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,9R,10R,12aS,14aR,14bR)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(E)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxane-2-carboxylic acid
• Molecular Formula: C₅₅H₈₆O₂₄
• Molecular Weight: 1131.26
• CAS Registry Number: 123748-68-5
• EC Number: 683-254-0
• SMILES: C/C=C(C)/C(=O)O[C@H]1[C@@H]([C@@]2([C@@H](C[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H]([C@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)[C@@H]2CC1(C)C)C)O)CO)OC(=O)C

Properties

• Density: 1.5±0.1 g/cm³, Calc.^*, 1.46 g/mL (Expl.)
• Index of Refraction: 1.628, Calc.^*
• Boiling Point: 1140.6±65.0 °C (760 mmHg), Calc.^*
• Flash Point: 311.8±27.8 °C, Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Safety Data

• Hazard Symbols: GHS07;GHS09 Warning
• Risk Statements: H302+H332-H302-H319-H332-H335-H411
• Safety Statements: P261-P264-P264+P265-P270-P271-P273-P280-P301+P317-P304+P340-P305+P351+P338-P317-P319-P330-P337+P317-P391-P403+P233-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Acute toxicity	Acute Tox.	4	H332
Acute toxicity	Acute Tox.	4	H302

Discovery and Applications

Escin IA is a naturally occurring triterpenoid saponin derived from the seeds of the horse chestnut tree (*Aesculus hippocastanum*). This compound is a significant bioactive component of escin, a complex mixture of saponins, and has attracted attention due to its wide-ranging pharmacological properties. Escin IA, along with its related analogs, contributes to the therapeutic efficacy of horse chestnut extracts, which have been traditionally used for centuries in herbal medicine.

The discovery and structural elucidation of Escin IA emerged from extensive phytochemical studies conducted on horse chestnut seeds in the mid-20th century. Researchers isolated the saponin fractions and used advanced chromatographic techniques and spectroscopic methods to identify and characterize Escin IA. Its structure consists of a hydrophobic aglycone backbone linked to sugar moieties, which are key to its amphiphilic properties. This amphiphilicity underpins the compound’s ability to interact with biological membranes and its broad range of biological activities.

Escin IA is most widely recognized for its anti-inflammatory, venotonic, and vascular-protective properties. These attributes make it a key therapeutic agent in the treatment of chronic venous insufficiency (CVI), a condition characterized by impaired blood flow in the veins, leading to swelling, pain, and varicose veins. Escin IA works by improving venous tone, reducing capillary permeability, and mitigating inflammation. Its mechanism of action involves inhibiting the activity of enzymes like hyaluronidase and elastase, which are responsible for degrading extracellular matrix components and increasing vascular permeability. These effects contribute to reducing edema and enhancing venous return.

Beyond CVI, Escin IA has demonstrated efficacy in reducing post-surgical and traumatic edema. Its ability to alleviate swelling and inflammation has led to its inclusion in topical formulations and oral supplements designed for patients recovering from injuries or surgical procedures. Clinical trials have shown that Escin IA reduces edema and accelerates recovery in these contexts, highlighting its therapeutic versatility.

Recent studies have expanded the scope of Escin IA’s pharmacological applications. Research indicates that it possesses potent antioxidant properties, which may play a role in protecting cells from oxidative stress. This has opened avenues for exploring its use in conditions associated with oxidative damage, such as cardiovascular diseases and neurodegenerative disorders. Additionally, Escin IA has exhibited anticancer potential in preclinical studies, where it has been shown to induce apoptosis and inhibit the proliferation of cancer cells. While these findings are promising, further research is necessary to fully elucidate its mechanisms and evaluate its clinical relevance in oncology.

Escin IA also finds applications in dermatology and cosmetic formulations due to its anti-inflammatory and vascular-protective properties. It is used in creams and gels aimed at reducing under-eye puffiness, improving skin elasticity, and alleviating redness caused by conditions such as rosacea. Its ability to enhance microcirculation and reduce capillary fragility makes it a valuable ingredient in products targeting sensitive or damaged skin.

Despite its broad therapeutic potential, the use of Escin IA is not without challenges. The compound’s amphiphilic nature poses solubility issues, and its oral bioavailability is limited due to extensive metabolism and poor absorption. Researchers are investigating novel delivery systems, such as nanoparticles and liposomes, to enhance its stability, solubility, and bioavailability. These advancements could significantly expand the utility of Escin IA in medical and cosmetic applications.

In conclusion, Escin IA is a remarkable natural compound with a diverse array of pharmacological activities. Its established use in treating venous disorders and its emerging potential in other medical fields underscore its importance in both traditional and modern therapeutics. Continued research into its mechanisms of action and formulation strategies will likely pave the way for new applications and improved efficacy.

References

2012. Comparative pharmacokinetics and bioavailability of escin Ia and isoescin Ia after administration of escin and of pure escin Ia and isoescin Ia in rat. Journal of Ethnopharmacology.
DOI: 10.1016/j.jep.2011.11.003

2014. Pharmacokinetics of escin Ia in rats after intravenous administration. Journal of Ethnopharmacology.
DOI: 10.1016/j.jep.2014.08.032

2016. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression. Oncotarget.
DOI: 10.18632/oncotarget.8152